SK15302002A3 - Antagonista receptora VEGFR a jeho použitie - Google Patents

Antagonista receptora VEGFR a jeho použitie Download PDF

Info

Publication number
SK15302002A3
SK15302002A3 SK1530-2002A SK15302002A SK15302002A3 SK 15302002 A3 SK15302002 A3 SK 15302002A3 SK 15302002 A SK15302002 A SK 15302002A SK 15302002 A3 SK15302002 A3 SK 15302002A3
Authority
SK
Slovakia
Prior art keywords
antagonist
vegfr
cells
vegf
chemotherapeutic agent
Prior art date
Application number
SK1530-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Larry Witte
Shahin Rafii
Original Assignee
Imclone Systems Incorporated
Cornell Research Foundation Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Incorporated, Cornell Research Foundation Inc. filed Critical Imclone Systems Incorporated
Publication of SK15302002A3 publication Critical patent/SK15302002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SK1530-2002A 2000-03-31 2001-03-30 Antagonista receptora VEGFR a jeho použitie SK15302002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54077000A 2000-03-31 2000-03-31
PCT/US2001/010504 WO2001074296A2 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists

Publications (1)

Publication Number Publication Date
SK15302002A3 true SK15302002A3 (sk) 2004-06-08

Family

ID=24156859

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1530-2002A SK15302002A3 (sk) 2000-03-31 2001-03-30 Antagonista receptora VEGFR a jeho použitie

Country Status (10)

Country Link
EP (1) EP1436000A2 (ja)
JP (1) JP2004501070A (ja)
KR (1) KR20020087453A (ja)
AU (1) AU2001249736A1 (ja)
CA (1) CA2404040A1 (ja)
CZ (1) CZ20023518A3 (ja)
IL (1) IL151992A0 (ja)
RU (1) RU2002129574A (ja)
SK (1) SK15302002A3 (ja)
WO (1) WO2001074296A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174632A1 (en) 2000-09-11 2011-10-28 Novartis Vaccines & Diagnostic Quinolinone derivatives
ES2324981T3 (es) 2000-12-21 2009-08-21 Smithkline Beecham Corporation Pirimidinaminas como moduladores de la angiogenesis.
WO2003006059A1 (en) * 2001-07-13 2003-01-23 Imclone Systems Incorporated Vegfr-1 antibodies to treat breast cancer
DK1916001T3 (da) 2002-03-04 2011-07-18 Imclone Llc KDR-specifikke humane antistoffer og anvendelser deraf
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
CN1890234A (zh) 2003-12-23 2007-01-03 辉瑞大药厂 新颖的喹啉衍生物
TWI571473B (zh) 2011-11-02 2017-02-21 埃派斯進有限公司 抗ｋｄｒ抗體及使用方法

Also Published As

Publication number Publication date
JP2004501070A (ja) 2004-01-15
CA2404040A1 (en) 2001-10-11
WO2001074296A2 (en) 2001-10-11
AU2001249736A1 (en) 2001-10-15
IL151992A0 (en) 2003-04-10
CZ20023518A3 (cs) 2004-04-14
WO2001074296A3 (en) 2004-05-06
EP1436000A2 (en) 2004-07-14
KR20020087453A (ko) 2002-11-22
RU2002129574A (ru) 2004-04-20

Similar Documents

Publication Publication Date Title
JP7301106B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
ES2435727T3 (es) Anticuerpo contra PDGFR-alfa para uso en el tratamiento de tumores
US9249220B2 (en) Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
US8933202B2 (en) AXL antibodies
KR101806323B1 (ko) Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
CA2741127C (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
KR20180133399A (ko) 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
KR20210058811A (ko) 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
JP2021520393A (ja) コネキシン４３抗体およびその使用
CA3166328A1 (en) Tgf-beta inhibitors and use thereof
SK15302002A3 (sk) Antagonista receptora VEGFR a jeho použitie
US20150152193A1 (en) Axl antibodies
KR20070001883A (ko) 항-아이쥐에프-아이 수용체 항체
US11365250B2 (en) Compositions and methods for cancer therapy
BRPI0622074B1 (pt) Anticorpo ou fragmento de anticorpo humano isolado específico para pdgfr-alfa, polinucleotídeo e vetor de expressão

Legal Events

Date Code Title Description
FC9A Refused patent application